Strong growth in Libtayo sales and increased collaboration revenues from Sanofi aided the results but were somewhat offset by lower Eylea’s sales. Additionally, Regeneron initiated a quarterly ...
Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...
Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
and combinations with existing drugs like Libtayo. These pipeline developments provide multiple avenues for future growth and could help offset potential revenue losses from Eylea biosimilar ...
Regeneron Pharmaceuticals ... injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
The LAG-3 next-generation therapies market is expected to grow in the upcoming years owing to the potential entry of major LAG-3 candidates and their readily uptake, increase in incident cases of ...
In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss tied to the variants of the otoferlin gene, 10 out of 11 have showed notable improvements in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback